Combination therapies in multiple myeloma show superior efficacy over monotherapies, with higher response rates and progression-free survival. Monotherapy with agents like Empliciti and Darzalex shows ...

In an interview with CURE, Craig Hofmeister provided insight into the potential for combination regimens in relapsed/refractory patients with multiple myeloma. Findings from early clinical trials are ...

A. Keith Stewart, MB, ChB: Outcomes for multiple myeloma patients have improved dramatically over the past decade. This has come about as the result of the introduction of a whole new class of novel ...

Please provide your email address to receive an email when new articles are posted on . Patients had a reduced risk for disease progression or death when treated with daratumumab-lenalidomide vs.

Results from a subgroup analysis of the phase 3 ENDEAVOR study and a phase 2 study in diffuse large B cell lymphoma patients were presented at the annual meeting of the American Society of Hematology.

Please provide your email address to receive an email when new articles are posted on . Researchers observed responses at all dose levels, with the recommended phase 2 regimen linked to durable ...